Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 2—February 2022
Research Letter

Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia

Ekaterina Krieger, Alexander Kudryavtsev, Ekaterina Sharashova, Vitaly Postoev, Natalia Belova, Leonid Shagrov, Julia Zvedina, Oxana Drapkina, Anna Kontsevaya, Svetlana Shalnova, Tormod Brenn, Vladimir M. Shkolnikov, Rosalind M. Eggo, and David A. LeonComments to Author 
Author affiliations: UiT The Arctic University of Norway, Tromso, Norway (E. Krieger, A. Kudryavtsev, E. Sharashova, T. Brenn, D.A. Leon); Northern State Medical University of the Ministry of Health of the Russian Federation, Arkhangelsk, Russia (E. Krieger, A. Kudryavtsev, V. Postoev, N. Belova, L. Shagrov, J. Zvedina); National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia (O. Drapkina, A. Kontsev, S. Shalnova); Max-Planck-Institute for Demographic Research, Mecklenburg, Germany (V.M. Shkolnikov); National Research University Higher School of Economics, Moscow (V.M. Shkolnikov, D.A. Leon); London School of Hygiene & Tropical Medicine, London, UK (R.M. Eggo, D.A. Leon)

Main Article

Table

Seroprevalence of severe acute respiratory syndrome coronavirus 2 in adults, Arkhangelsk, Russia

Characteristic Unvaccinated
Vaccinated*
Total
No. seropositive/total (%) Adjusted seroprevalence, % (95% CI)† No. seropositive/total (%) Adjusted seroprevalence, % (95% CI)† No. seropositive/total (%) Adjusted seroprevalence, % (95% CI)†
Sex
F 332/553 (60) 67.4 (58.4–77.9) 72/81 (89) 99.7 (87.1–99.9) 404/634 (64) 71.5 (62.6–82.3)
M
208/352 (59)
66.3 (56.5–77.3)

78/81 (96)
100 (93.2–100)

286/433 (66)
74.1 (64.5–85.6)
Age, y
40–54 291/461 (63) 70.8 (61.4;81.8) 35/38 (92) 100 (84.8–100) 326/499 (65) 73.3 (64.0–84.6)
55–64 181/317 (57) 64.1 (54.1–75.0) 38/43 (88) 99.1 (82.6–100) 219/360 (61) 68.3 (58.4–79.4)
>65
68/127 (54)
60.1 (46.9–73.1)

77/81 (95)
100 (92.4–100)

145/208 (70)
78.2 (67.0–91.2)
Education
Secondary and lower 26/47 (55) 62.1 (42.7–81.0) 9/9 (100) 100 (66.7–100) 35/56 (63) 70.1 (52.5–88.1)
Specialized secondary 253/433 (58) 65.6 (56.1–76.0) 81/87 (93) 100 (91.2–100) 334/520 (64) 72.1 (62.9–83.2)
Higher
261/425 (61)
68.9 (59.3–79.8)

60/66 (91)
100 (88.0–100)

321/491 (65)
73.3 (64.0–84.6)
Week of test
7–14 395/651 (61) 68.1 (59.3–78,4) 49/58 (84) 94.8 (81.0–100) 444/709 (63) 70.3 (61.6–80.8)
15–21
145/254 (57)
64.0 (53.4–75.3)

101/104 (97)
100 (94.8–100)

246/358 (69)
77.1 (67.1–89.1)
Self-reported prior symptoms of infection
No 172/477 (36) 40.5 (31.7–47.8) 133/143 (93) 100 (92.9–100) 305/620 (49) 55.2 (46.6–64.0)
Yes 248/256 (97) 100 (96.9–100) 8/9 (89) 99.7 (56.8–100) 256/265 (97) 100 (96.7–100)
Do not know
120/172 (70)
78.3 (66.5–91.6)

9/10 (90)
100 (60.4–100)

129/182 (71)
79.5 (68.1–92.8)
Total 540/905 (60) 66.9 (58.6–76.9) 150/162 (93) 100 (92.9–100) 690/1067 (65) 72.6 (64.2–83.1)

*Received >1 dose. †Values >100% were rounded to 100%. ‡Weeks 7–14 are February 24–April 11 and weeks 15–21 are April 12–May 28, 2021.

Main Article

Page created: December 08, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external